Company intelligence / Profile preview
TollereBio
Baltimore, Maryland, USAtollerebio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
TollereBio is developing novel, cost-effective vaccine adjuvants using its BECC platform. Preclinical studies have shown that these adjuvants enhance antibody production, improve T-cell activation, and extend the durability of vaccine protection compared to existing adjuvants. Four BECC-derived adjuvants have been highlighted by the NIAID Vaccine Adjuvant Compendium[2][3].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Vaccine adjuvants (specifically, lipid A mimetics and TLR4 agonists)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
University of Maryland, Baltimore (technology licensing and ongoing collaboration)[2][3]
Beyond the preview
Go deeper on TollereBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TollereBio.